

Prostate Cancer Drugs Market Players Increasingly Invest In New Therapies

*The Business Research Company's
Prostate Cancer Drugs Global Market
Report 2022 – Market Size, Trends, And
Global Forecast 2022-2026*


LONDON, GREATER LONDON, UK,
March 15, 2022 /EINPresswire.com/ --
[Prostate cancer drugs market trends](#)

include the use of combination therapy to treat prostate cancer which is gaining popularity in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer.

In June 2021, Bayer, a Germany based pharmaceuticals company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc for an undisclosed amount. With this acquired Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology.

Read more on the Global Prostate Cancer Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report>



The global [prostate cancer drugs market size](#) is expected to grow from \$16.09 billion in 2021 to \$17.64 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global prostate cancer drugs market share is expected to reach \$23.95 billion in 2026 at a CAGR of 8.0%.

Major players covered in the global prostate cancer drugs industry are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Novartis and F. Hoffmann-La Roche AG.

The increasing male geriatric population is a major driver for the prostate cancer drugs market growth. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40.

TBRC's global prostate cancer drugs market report is segmented by type into hormone sensitive prostate cancer, hormone refractory prostate cancer, by therapy into hormonal therapy, chemotherapy, immunotherapy, targeted therapy, by end-user into hospitals, clinics, others.

Prostate Cancer Drugs Global Market Report 2022 – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By End User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a prostate cancer drugs market overview, prostate cancer drugs market forecast, prostate cancer drugs market size and growth for the whole market, prostate cancer drugs market segments, prostate cancer drugs market geographies, prostate cancer drugs market trends, prostate cancer drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Prostate Cancer Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Pancreatic Cancer Drugs Global Market Report 2022 – By Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), By End User (Hospitals, Clinics, Others), By Drugs (Afinitor, Erlotinib, Hydrochloride Everolimus, 5-FU, Flurouracil, Gemcitabine, Abraxane) – Market Size, Trends, And

Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report>

Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report>

Cancer Diagnostics Global Market Report 2021 - By Products (Companion Diagnostics, Molecular Diagnostics), By End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report>

Know More About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/565569719>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.